PT Journal
AU Frysak, Z
   Schovanek, J
   Iacobone, M
   Karasek, D
TI Insulin-like Growth Factors in a clinical setting: Review of IGF-I
SO Biomedical papers
PY 2015
BP 347
EP 351
VL 159
IS 3
DI 10.5507/bp.2015.041
DE Somatomedins; Insulin-Like Growth Factor I; II; IGF-I receptor; Human Growth Hormone; Recombinant Human Growth Hormone; Acid Labile Subunit; IGF Binding Proteins; Mecasermin; Insulin Receptor Isoform A; acromegaly; growth hormone deficiency
AB Background and Aims: Interest in growth hormone (GH) is inextricably linked to the need for in depth understanding of the somatomedins (insulin-like growth factors) which are polypeptides structurally similar to insulin and with broad physiological activity. To date, the most commonly known is Insulin-Like Growth Factor I (IGF-I). Despite considerable current knowledge of IGF-I, however, its bioactivity is incompletely understood. Measurement of IGF-I is of the utmost importance in the diagnosis and treatment of, for example acromegaly and growth hormone deficiency. The development of recombinant IGF-I, has allowed its use in such cases. Clinical practice, however, shows that few young/adult patients will benefit from treatment with the rIGF-I, mecasermin, given the number of adverse effects found. This review focuses on current knowledge mainly related to IGF-I and the use of its recombinant form (rIGF-I) in clinical practice. Several functions of IGI-II have been elucidated but their clinical significance is unclear.
ER